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Background: Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827)
of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease
progressed following initial response and who received a second course of pembrolizumab were also analyzed.
Patients and methods: Patients aged 18 years with previously treated or treatment-naive advanced/metastatic melanoma
received pembrolizumab 2mg/kg every 3weeks, 10mg/kg every 3weeks, or 10mg/kg every 2weeks until disease progression,
intolerable toxicity, or patient/investigator decision to withdraw. Kaplan–Meier estimates of overall survival (OS) and
progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response
criteria by investigator assessment (data cut-off, September 1, 2017).
Results: KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55months. Estimated 5-year OS was 34%
in all patients and 41% in treatment-naive patients; median OS was 23.8months (95% CI, 20.2–30.4) and 38.6months (95% CI,
27.2–not reached), respectively. Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients;
median PFS was 8.3months (95% CI, 5.8–11.1) and 16.9months (95% CI, 9.3–35.5), respectively. Median response duration was
not reached; 73% of all responses and 82% of treatment-naive responses were ongoing at data cut-off; the longest response
was ongoing at 66months. Four patients [all with prior response of complete response (CR)] whose disease progressed during
observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after
data cut-off). Treatment-related AEs (TRAEs) occurred in 86% of patients and resulted in study discontinuation in 7.8%; 17%
experienced grade 3/4 TRAE.
Conclusions: This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms
the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma.
Clinical Trial Registry: ClinicalTrials.gov, NCT01295827.
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Introduction
The incidence of melanoma is increasing, with up to 20% of
patients expected to develop advanced/metastatic disease [1].
The historical 10-year survival rate in patients with advanced
melanoma was approximately 10% [2–4]; experience with mono-
therapy directed against cytotoxic T-lymphocyte-associated
protein-4 (CTLA-4) [5–7] has increased this survival rate up to
22% [4]. Given the increased response and 1-year survival rates
with programmed death (PD-1) inhibitors [8–12], a complemen-
tary increase in 5-year survival is expected.
Two PD-1 inhibitors, pembrolizumab and nivolumab, have
been evaluated extensively in patients with melanoma; both block
the interaction between PD-1 and its ligands, PD-L1 and PD-L2,
to reinstate the antitumor immune response [13, 14]. In three
separate trials of advanced melanoma (KEYNOTE-001,
KEYNOTE-002, and KEYNOTE-006), which included previously
treated and treatment-naive patients, pembrolizumab monother-
apy provided durable response rates of 30%–40% [8, 10, 12, 15–
18]. Similarly, in the advanced melanoma cohort of patients from
the dose-ranging phase I CA209-003 study, treatment with nivo-
lumab resulted in a cumulative response rate of 28% [19] and 5-
year overall survival (OS) rate of 34% [20]. Subsequent phase III
studies of nivolumab as monotherapy in treatment-naive and
previously treated advanced melanoma yielded durable response
rates of 32% and 40%, respectively [9, 11]. Reports of long-term
efficacy and safety in patients treated with PD-1 inhibitors for
advanced melanoma are limited.
In the large phase Ib KEYNOTE-001 study, pembrolizumab
monotherapy provided 3-year OS rates of 41% for patients with
ipilimumab-treated and ipilimumab-naive advanced melanoma
and 45% for patients with treatment-naive advanced melanoma
[12]. Median OS was 23.8 months (95% CI, 20.2–29.0) overall
and 20.0 (95% CI, 17.8–27.1), and 28.8 (95% CI, 23.1–32.2)
months for ipilimumab-treated and treatment-naive patients, re-
spectively. Five-year follow-up data of patients treated with pem-
brolizumab are presented, including data on retreatment of
patients receiving a second-course of pembrolizumab on disease
progression after first course therapy.
Patients and methods
Patients
KEYNOTE-001 (NCT01295827) was an open-label, phase Ib clinical trial that
included multiple cohorts of patients with advanced solid tumors, including
melanoma and non-small-cell lung cancer. Eligibility criteria for the
ipilimumab-treated or ipilimumab-naive melanoma cohorts are published
[8]. Briefly, eligible patients were 18 years of age with confirmed advanced
or metastatic melanoma, measurable disease per immune-related response
criteria (irRC) [21], Eastern Cooperative Oncology Group performance status
(ECOG PS) 0 or 1, no history of chemotherapy within 4 weeks of first pem-
brolizumab dose, and no history of treatment targeting the PD-1/PD-L1 path-
way. Patients were recruited between December 2011 and September 2013,
and they enrolled in nonrandomized and randomized cohorts.
Study design
The study protocol and amendments were approved by the appropriate
institutional review board or independent ethics committee at each
participating institution. The study was conducted in accordance with
the protocol, good clinical practice guidelines, provisions of the
Declaration of Helsinki, and all local regulations. All patients provided
written informed consent to participate.
Treatment and assessments
Patients received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every
3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable
toxicity, or patient or investigator decision to withdraw. After a protocol
amendment, patients who experienced complete response (CR), con-
firmed by imaging scans 4 weeks apart, and who received pembrolizu-
mab treatment for 6 months could, at the discretion of the investigator
and if the patient desired, discontinue treatment after receiving2 pem-
brolizumab doses beyond the initial determination of CR. Patients were
eligible to receive a second course of pembrolizumab if they stopped ini-
tial treatment after attaining investigator-determined CR per irRC,
investigator-determined partial response (PR), or stable disease (SD)
after 2 years of treatment with pembrolizumab; were treated for
24 weeks before discontinuing therapy; experienced investigator-
determined progression after stopping their initial treatment; had an
ECOG status of 0 or 1; and did not receive any cancer treatment since the
last dose of pembrolizumab. Tumor response was assessed every 12 weeks
by independent central review using Response Evaluation Criteria in
Solid Tumors (RECIST) v1.1 (for determining efficacy) and by investiga-
tor review using irRC (for disease management). For all analyses of re-
sponse rates and PFS, tumor response was assessed by investigator review
using irRC; for the biomarker analyses, response was assessed by central
review per RECIST v1.1.
Gene expression analysis
The correlation between response to pembrolizumab and gene expres-
sion profile (GEP) was explored using the 18-gene T-cell-inflamed GEP
[CCL5, CD27, CD274 (PD-L1), CD276 (B7-H3), CD8A, CMKLR1,
CXCL9, CXCR6, HLA-DQA1, HLA-DRB1, HLA-E, IDO1, LAG3, NKG7,
PDCD1LG2 (PD-L2), PSMB10, STAT1, and TIGIT]; development is
described elsewhere [22]. The 18-gene T-cell-inflamed GEP consists of
genes related to antigen presentation, chemokine expression, cytolytic ac-
tivity, and adaptive immune resistance. GEP scores were computed by
taking a weighted sum of the housekeeping-normalized values of the 18
genes on the GEP18 signature.
Statistical analysis
All analyses were performed in the treated population, defined as all
patients who received 1 dose of pembrolizumab. The Kaplan–Meier
(KM) method was used to estimate the OS curve in each patient popula-
tion; the nonparametric KM method was used to estimate the
progression-free survival (PFS) curve in each treatment and duration of
response. Duration of response was calculated from time of first response
to time of progression. Patients without a progression event were cen-
sored at the date of the last non-PD assessment. Best overall response
(BOR) was based on investigator assessment. Analyses were performed
using a data cut-off date of September 1, 2017.
Results
KEYNOTE-001 enrolled 655 patients in the melanoma cohorts;
of these, 151 were treatment-naive and 496 were previously
treated (205 received 1 prior therapy, 178 received 2 prior thera-
pies, 113 received 3 prior therapies); 8 patients had uveal mel-
anoma and had received no prior systemic therapy. Baseline
characteristics according to treatment group are published and
were well balanced [8]. Supplementary Table S1, available at
Annals of Oncology Original article
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Annals of Oncology online, presents baseline characteristics in the
melanoma cohorts. Median duration of follow-up was 55 months
(range: 48–69), and median duration of exposure to pembrolizu-
mab was 5.6 months (range: 1 day–67 months). At data cut-off,
33 (5%) patients, including 2 on second course, were still receiv-
ing treatment, and 569 patients (87%) discontinued because of
progressive disease (PD; n¼ 275; 42%), adverse events (n¼ 166;
25%), physician decision (n¼ 80; 12%), patient withdrawal
(n¼ 36; 5%), protocol violation (n¼ 8; 1%), or lost to follow-up
(n¼ 4; <1%) (supplementary Table S2, available at Annals of
Oncology online).
At data cut-off, 63% (n¼ 412) of all patients and 54% (n¼ 81)
of treatment-naive patients had died. The estimated 5-year OS rate
was 34% in all patients and 41% in treatment-naive patients.
Median OS was 23.8 months (95% CI, 20.2–30.4) in all patients
and 38.6 months (95% CI, 27.2–NR) in treatment-naive patients
(Figure 1A and B). The 5-year estimated PFS rate was 21% and
29%, respectively. Median PFS was 8.3 months (95% CI, 5.8–11.1)
in all patients and 16.9 months (95% CI, 9.3–35.5) in treatment-
naive patients (Figure 1C and D).
Among all 655 treated patients, 104 (16%) achieved CR, 163
(25%) achieved PR, and 156 (24%) achieved SD, for a disease con-
trol rate (DCR) of 65% (Table 1; Figure 2). In total, 164 (25%)
patients experienced a BOR of PD. Of the 423 patients who con-
tributed to the DCR, 165 (13 CR, 61 PR, 91 SD) experienced subse-
quent disease progression. Median time to response was
2.8 months (range: 0.5–49.6), and median duration of response
was NR (range: 1.3þ to 66.3þ months) (supplementary Figure
S1A, available atAnnals of Oncology online). Of those who achieved
CR, median time to response was 2.8 months (range: 0.5–11.0),
and median duration of response was NR (range: 3.8þ to 66.3þ
months). Response was ongoing in 89% (n¼ 93) of patients who
achieved CR. In patients with PR, median time to response was
2.8 months (range: 1.7–49.6), and median duration of response
was NR (range: 1.3þ to 63.5þ months). At data cut-off, response
was ongoing in 63% (n¼ 102) of patients who achieved PR.
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Figure 1. Kaplan–Meier estimates of OS in (A) all patients and (B) treatment-naive patients and estimates of PFSa based on irRC (investigator
review) [21] in (C) all patients and (D) treatment-naive patients. irRC, immune-related response criteria; NR, not reached; OS, overall survival;
PFS, progression-free survival. aTwo patients who had PD after a first course of pembrolizumab and received a second course of pembrolizu-
mab were not included in this analysis because they did not meet the criteria for confirming progression (i.e. they did not meet the two-
image criterion for timepoint overall response of PD).
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In the treatment-naive population, BOR was CR in 38 patients
(25%); 40 (27%) achieved PR and 30 (20%) experienced SD, for
a DCR of 72% (Table 1). BOR in 32 patients (21%) was PD.
Median time to response was 2.8 months (range: 2.5–32.0), and
median duration of response was NR (range: 1.3þ to 60.8þ
months) (supplementary Figure S1B, available at Annals of
Oncology online). Of the 38 patients who achieved CR, median
time to response was 2.8 months (range: 2.5–8.3), and median
duration of response was NR (range: 6.0þ to 60.8þ months).
Response was ongoing in 35 patients (92%) at the time of data
cut-off. Of the 40 who achieved PR, median time to response was
2.8 months (range: 2.5–32.0), and median duration of response
was NR (range: 1.3þ to 51.4þmonths). Response was ongoing in
29 treatment-naive patients (73%) who achieved PR.
Response by prior ipilimumab treatment was also evaluated
(supplementary Table S3, available at Annals of Oncology online).
The overall response rate was slightly higher in ipilimumab-naive
patients (46%) than in ipilimumab-exposed patients (36%);
DCR was similar between groups (66% and 64%, respectively).
Seventy-two patients who met eligibility criteria for stopping
pembrolizumab discontinued treatment to enter observation, per
the protocol. Sixty-seven achieved CR and 5 achieved PR as BOR.
Median time to first response for them was 2.8 months (range:
0.5–13.8) after treatment initiation. Seven patients had PD (6 CR,
1 PR) after stopping pembrolizumab; most (90%) responses were
maintained (Figure 2). Four patients, all who achieved CR as a
first response, received second-course pembrolizumab (Table 2).
BOR on second-course treatment was 1 CR and 1 SD
(patient achieved a PR of 2 weeks after data cut-off); 2 had subse-
quent PD.
Analysis of the 18-gene GEP demonstrated an association be-
tween GEP score and overall response to pembrolizumab (sup-
plementary Figure S2A, available at Annals of Oncology online) in
treatment-naive and treatment-exposed patients (supplementary
Figure S2B, available at Annals of Oncology online) and in
ipilimumab-naive and ipilimumab-exposed patients (supple-
mentary Figure S2C, available atAnnals of Oncology online).
Treatment-related AEs occurred in 562 patients (86%) (sup-
plementary Table S4, available at Annals of Oncology online); 114
(17%) experienced grade 3–4 treatment-related AEs, 65 (10%)
discontinued because of a treatment-related AE and none experi-
enced treatment-related death. Immune-mediated AEs are shown
in supplementary Figure S3, available at Annals of Oncology
online.
Discussion
In this analysis of patients with advanced melanoma treated with
pembrolizumab in KEYNOTE-001, the estimated OS rate at
0 12 24 36
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Figure 2. Responders who stopped pembrolizumab during observation (n¼ 72). CR, complete response; PD, progressive disease; PR, partial
response.
Table 1. Best overall responses based on irRC (investigator review) [21] in
all patients and treatment-naive patientsa
Response Total, % (95% CI) Treatment-naive, % (95% CI)
N5 655 n5151
ORR 41 (37–45) 52 (43–60)
DCR 65 (61–68) 72 (64–79)
Best response
CR 16 (13–19) 25 (19–33)
PR 25 (22–28) 27 (20–34)
SD 24 (21–27) 20 (14–27)
PD 25 (22–29) 21 (15–29)
No assessment 10 (8–13) 7 (4–13)
aOnly confirmed responses.
CR, complete response; DCR, disease control rate; irRC, immune-related
response criteria; ORR, overall response rate; PD, progressive disease; PR,
partial response; SD, stable disease.
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5 years in the overall population and in those who were
treatment-naive was comparable to the 4-year OS rate. The per-
centage of patients with an ongoing response was higher in those
who were treatment-naive than in all patients and numerically
higher in patients who achieved CR than in those who achieved
PR. DCR was unaffected by prior ipilimumab exposure. These
data, which represent the longest follow-up of pembrolizumab
published in any cancer histology to date, confirm the durable
antitumor activity of pembrolizumab in advanced and metastatic
melanoma. The safety profile of pembrolizumab in patients with
melanoma has been established partly through KEYNOTE-001;
with continued follow-up, no new safety signals have been identi-
fied in this study.
Five-year OS rates observed with pembrolizumab in this ana-
lysis were significantly higher than those reported for ipilimumab
monotherapy (12.3%–28.4%) [23]. They represent the first long-
term follow-up data from a trial evaluating pembrolizumab in
patients with advanced and metastatic melanoma. As with the
results presented here [pembrolizumab, 5-year OS rates: 34% (all
patients) versus 41% (treatment-naive patients)], slightly higher
5-year survival rates were achieved with ipilimumab in
treatment-naive patients [ipilimumab, 5-year OS rates: 12.3%–
28.4% (all patients) versus 21.4%–49.5% (treatment-naive
patients)]. Single-agent nivolumab demonstrated an OS rate of
34% and median OS of 17.3 months after 45-months’ follow-
up in heavily pretreated patients with advanced melanoma [20].
A plateau in OS was seen at approximately 48 months, indicative
of a long-term benefit in some patients [20]. In the phase III
KEYNOTE-006 trial in which a head-to-head comparison of ipi-
limumab and pembrolizumab was conducted, 48-month OS
rates were 42% with pembrolizumab and 34% with ipilimumab
(manuscript in preparation), confirming the superiority of anti-
PD-1 therapy in the first-line setting over anti-CTLA-4 and other
standard therapies. This assertion is further supported by the ro-
bust duration of response.
Previous work has demonstrated correlation between pembro-
lizumab response rate, PFS, and OS and pretreatment PD-L1 ex-
pression in tumor biopsies from patients in KEYNOTE-001,
although patients with PD-L1-negative tumors may also achieve
durable responses [24]. At the molecular level, long-term
responses observed with pembrolizumab in KEYNOTE-001 may
be explained by induction of several cytolysis-associated and nat-
ural killer-associated genes in the tumor through PD-1 [25]. In
patients treated with pembrolizumab for advanced/metastatic
melanoma, long-term responses may be maintained through
prominent expansion of CD8þ memory cells [26]. In the present
analysis, the distribution of 18-gene GEP scores [22] was higher
in responders than in nonresponders, regardless of previous ex-
posure to any treatment, including ipilimumab.
Data are limited describing outcomes in patients who experi-
ence disease progress and are retreated with a second course of
checkpoint inhibitor therapy. In a retrospective review of 8
patients retreated with nivolumab, response on first-course treat-
ment was 3 CR along with 3 SD before therapy was discontinued
(due to PD in 7 patients and grade 3 colitis in 1 patient) [27]. The
median nivolumab treatment period was 4.3 months. Following
retreatment, 2 patients (25%) achieved PR and 3 (38%) achieved
SD, for a response rate of 25% (2 patients) and DCR of 62% (5/8
patients). In another study of nivolumab (N¼ 107), all 5 patients
who discontinued treatment for100 days and experienced sub-
sequent disease progression achieved durable disease control and
were alive at 5 years [20]. In a preliminary analysis of the CA184-
025 study evaluating ipilimumab in advanced melanoma
(N¼ 855), 51 patients (6%) who achieved disease control were
retreated on disease progression [28]. Of these, 28 (55%)
regained disease control and 42% were alive 2 years after the first
induction dose. In a follow-up analysis involving 122 patients, 7
(6%) achieved CR and 21 (17%) achieved PR for a BOR rate of
23%. Another 31 (25%) patients achieved SD for a DCR of 48%
[23]. Although patient numbers were low, survival outcomes of
patients who received second-course pembrolizumab in
KEYNOTE-001 compare favorably with those of other immuno-
therapies; 1 patient each achieved CR and SD (PR documented
2 weeks after data cut-off). Second-course pembrolizumab treat-
ment was also recently assessed in the phase III KEYNOTE-006
study of patients with ipilimumab-naive advanced melanoma. Of
the eight patients (first-course responses: 3 CR, 4 PR, 1 SD) who
received second-course pembrolizumab, 1 achieved CR, 3
achieved PR, 3 had SD, and 1 had PD [29]. This study reports
second-course pembrolizumab in patients with advanced
Table 2. Response with second course of pembrolizumab
Patient Exposure to
first course,
months
Best response
on first coursea
Time from
start of first
course to CR,
months
Time from
end of first
course to
PD, months
Exposure to
second course,
months
Time from
start of
second course
to responsea
(SD or CR), months
Time from start
of second course
to second course
progression, months
1 14.3 CR 2.8 37.3 2.1 NA 2.8c
2 18.0 CR 16.7 22.7 14.8 2.5 (SDb) NA
3 18.4 CR 3.6 14.0 15.0 6.2 (CR) NA
4 20.8 CR 19.7 5.5 4.2 NA 5.6
aBased on irRC (investigator review) [21].
bPR documented 2weeks after data cut-off.
cPatient died.
CR, complete response; irRC, immune-related response criteria; NA, not applicable; PD, progressive disease; PR, partial response; SD, stable disease.
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melanoma, and it underscores the role of reinduction as appro-
priate next-line therapy for patients who experience initial benefit
with pembrolizumab therapy.
Conclusions
This 5-year analysis of KEYNOTE-001 confirms the durable and
robust antitumor activity and safety of pembrolizumab for
treatment-experienced and treatment-naive patients with
advanced/metastatic melanoma. As second-course treatment,
pembrolizumab provides additional antitumor activity.
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